Low‐dose aspirin for prevention of cardiovascular disease in patients on hemodialysis: A 5‐y prospective cohort study

Research paper by Jun Liu, Yu Pan, Lei Chen, Qing Yan Qiao, Jing Wang, Li Hua Pan, Yan Hong Gu, Hui Fang Gu, Shun Kun Fu, Hui Min Jin

Indexed on: 09 Mar '16Published on: 01 Feb '16Published in: Hemodialysis International


Introduction Aspirin is an effective antiplatelet drug for preventing cardiovascular events in high‐risk subjects. However, for patients with chronic kidney disease and undergoing hemodialysis (HD), its preventive efficacy remains controversial. The present study aimed to determine whether aspirin therapy reduces the risk of cardiovascular disease (CVD) and all‐cause mortality in patients on HD. Methods We conducted a 5‐y prospective cohort study involving patients on HD. Major exposure variables included prescription of aspirin (100 mg/d) and no aspirin (nonaspirin). The primary outcomes included all‐cause death, cardiovascular events, hemorrhage, and ischemic stroke. The secondary outcome included bleeding events defined by the requirement of hospitalization. Findings In this study, 406 patients on regular HD were involved during a 5‐y follow‐up. Among these, 152 and 254 propensity‐matched patients were enrolled in the aspirin and nonaspirin cohort, respectively. The cumulative survival rate was not significantly higher in the aspirin than in the nonaspirin users (log rank χ2 = 1.080, P = 0.299). Aspirin use was not significantly associated with reduced all‐cause mortality, fatal and nonfatal congestive heart failure, as well as acute myocardial infarction and ischemic stroke. The risk of fatal cerebral hemorrhage was not significantly increased in the aspirin users (HR = 1.795, 95% CI 0.666–4.841, P = 0.174). After adjustment for other confounders, aspirin use was also not associated with decreased risk of all‐cause mortality and CVD. Discussion The present prospective cohort study suggests that low‐dose aspirin use is not associated with a significant decrease in the risks of all‐cause mortality, CVD, and stroke in population undergoing HD (ClinicalTrials.gov number, NCT02261025).